300 TECHNOLOGY SQUARE, CAMBRIDGE, MA
Other Events
Dianthus Therapeutics Enters Underwriting Agreement for $593.5M Offering
Material disclosure
Investor Presentation
Highlights Recent Business Achievements and Reports Q3 Financial Results
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities